Reslizumab | 合法藥品大搜索

Reslizumabisaninterleukin-5antagonistmonoclonalantibody.IL-5isthemajorcytokineresponsibleforthegrowthanddifferentiation,recruitment,activation,and ...

Pharmaceutical drug

Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5).[5] Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.[6]

In March 2016, the US Food and Drug Administration (FDA...